EMEA-000574-PIP02-12-M02

Key facts

Invented name
Blincyto
Active substance
blinatumomab
Therapeutic area
Oncology
Decision number
P/0401/2017
PIP number
EMEA-000574-PIP02-12-M02
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Treatment of acute lymphoblastic leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries
Amgen Europe B.V.
Tel. +44 (0)1223 420305
E-mail: pipenquiry@amgen.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating